<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117459</article-id><article-id pub-id-type="publisher-id">ACM-44050</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_24569516.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  致心律失常性右室心肌病致病基因突变、诊断及治疗研究新进展
  New Advances in the Research of Pathogenic Gene Mutation, Diagnosis and Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>柴</surname><given-names>俊武</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>延</surname><given-names>沁儒</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>静雅</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>承营</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曾</surname><given-names>迪</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>淄博市中心医院，山东 淄博</addr-line></aff><aff id="aff3"><addr-line>空军军医大学第二附属医院心血管内科，陕西 西安</addr-line></aff><aff id="aff2"><addr-line>空军军医大学基础医学院一大队一队，陕西 西安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3168</fpage><lpage>3175</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  致心律失常性右心室心肌病/发育不良(Arrhythmogenic Right Ventricular cardiomyopathy/dysplasia, ARVC/D)是一种以室性心律失常以及右、左心室功能障碍为特征的遗传性疾病；心肌细胞的纤维–脂肪替代；由于异质性的临床表现、家族内和家族间的表达高度可变以及不完全外显，其识别往往具有挑战性。本文通过对ARVC/D的致病基因突变、诊断进展及治疗进行综述，以通过基因突变检测筛选识别处于临床前阶段的患者，提高ARVC/D高危人群的早期诊断，为临床治疗提供参考。
   Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a genetic disease characterized by ventricular arrhythmia and right and left ventricular dysfunction; fiber-fat replacement; due to heterogeneous clinical manifestations, intra-family and inter-family expressions are highly variable and incompletely explicit, and their identification is often challenging. This article reviews the pathogenic gene mutations, diagnosis progress and treatment of ARVC/D in order to identify patients in the preclinical stage through gene mutation detection, improve the early diagnosis of ARVC/D high-risk groups, and provide references for clinical treatment.
 
</p></abstract><kwd-group><kwd>致心律失常性右心室心肌病/发育不良，致病基因突变，诊断，治疗, Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia</kwd><kwd> Pathogenic Gene Mutation</kwd><kwd> 
Diagnosis</kwd><kwd> Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>致心律失常性右心室心肌病/发育不良(Arrhythmogenic Right Ventricular cardiomyopathy/dysplasia, ARVC/D)是一种以室性心律失常以及右、左心室功能障碍为特征的遗传性疾病；心肌细胞的纤维–脂肪替代；由于异质性的临床表现、家族内和家族间的表达高度可变以及不完全外显，其识别往往具有挑战性。本文通过对ARVC/D的致病基因突变、诊断进展及治疗进行综述，以通过基因突变检测筛选识别处于临床前阶段的患者，提高ARVC/D高危人群的早期诊断，为临床治疗提供参考。</p></sec><sec id="s2"><title>关键词</title><p>致心律失常性右心室心肌病/发育不良，致病基因突变，诊断，治疗</p></sec><sec id="s3"><title>New Advances in the Research of Pathogenic Gene Mutation, Diagnosis and Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy<sup> </sup></title><p>Junwu Chai<sup>1</sup>, Qinru Yan<sup>2</sup>, Jingya Xu<sup>3</sup>, Chengying Yang<sup>2</sup>, Di Zeng<sup>2*</sup></p><p><sup>1</sup>The First Team of School of Basic Medicine, Air Force Military Medical University, Xi’an Shaanxi</p><p><sup>2</sup>Department of Cardiovascular Medicine, Second Affiliated Hospital of Air Force Military Medical University, Xi’an Shaanxi</p><p><sup>3</sup>Zibo Central Hospital, Zibo Shandong</p><p><img src="//html.hanspub.org/file/40-1572413x5_hanspub.png?20210723083000000" /></p><p>Received: Jun. 19<sup>th</sup>, 2021; accepted: Jul. 11<sup>th</sup>, 2021; published: Jul. 22<sup>nd</sup>, 2021</p><p><img src="//html.hanspub.org/file/40-1572413x6_hanspub.png?20210723083000000" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a genetic disease characterized by ventricular arrhythmia and right and left ventricular dysfunction; fiber-fat replacement; due to heterogeneous clinical manifestations, intra-family and inter-family expressions are highly variable and incompletely explicit, and their identification is often challenging. This article reviews the pathogenic gene mutations, diagnosis progress and treatment of ARVC/D in order to identify patients in the preclinical stage through gene mutation detection, improve the early diagnosis of ARVC/D high-risk groups, and provide references for clinical treatment.</p><p>Keywords:Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia, Pathogenic Gene Mutation, Diagnosis, Treatment</p><disp-formula id="hanspub.44050-formula29"><graphic xlink:href="//html.hanspub.org/file/40-1572413x7_hanspub.png?20210723083000000"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/40-1572413x8_hanspub.png?20210723083000000" /> <img src="//html.hanspub.org/file/40-1572413x9_hanspub.png?20210723083000000" /></p></sec><sec id="s5"><title>1. 引言</title><p>致心律失常性右心室心肌病/发育不良(Arrhythmogenic Right Ventricular cardiomyopathy/dysplasia, ARVC/D)由编码心肌细胞蛋白的基因突变引起，是年轻人和运动员心源性猝死(Sudden Cardiac Death, SCD)的主要原因 [<xref ref-type="bibr" rid="hanspub.44050-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44050-ref2">2</xref>]。它是一种原发性心肌病，主要表现为纤维脂肪替代和室性心律失常，发病率为1/1000~1/5000 [<xref ref-type="bibr" rid="hanspub.44050-ref3">3</xref>]。典型的ARVC/D是一种以室性心律失常或右、左心室功能障碍为特征的遗传性疾病；病理学研究发现，介入性椎间盘重塑发生在心脏结构变化之前，引发细胞凋亡、纤维脂肪替代、电传导障碍和其他相关效应 [<xref ref-type="bibr" rid="hanspub.44050-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.44050-ref4">4</xref>]。研究表明ARVC/D是由编码桥粒蛋白的基因突变引起的，改变的桥粒蛋白可能会损害细胞与细胞之间的粘附，导致细胞解偶联并导致肌细胞的纤维脂肪替代 [<xref ref-type="bibr" rid="hanspub.44050-ref5">5</xref>]。随着对ARVC/D致病基因突变的不断检出，人们发现非桥粒基因的突变也能引起患者心脏电传导和结构的改变，导致心脏泵功能被破坏，进一步诱导室性心律失常 [<xref ref-type="bibr" rid="hanspub.44050-ref6">6</xref>]。由于ARVC/D异质性的临床表现、家族内和家族间的高度可变表达以及不完全外显，其识别往往具有挑战性。本文通过对 ARVC/D的致病基因突变、诊断进展及治疗进行综述，以通过基因突变检测筛选识别处于临床前阶段的患者，提高ARVC/D高危人群的早期诊断，为临床治疗提供参考。</p></sec><sec id="s6"><title>2. 致病基因突变</title><p>目前已知ARVC/D相关基因15个，其中包含桥粒蛋白基因5个(JUP、DSP、PKP2、DSG2、DSC2)以及非桥粒蛋白基因10个(TMEM43、LMNA、DES、CTNNA3、PLN、TGFβ3、TTN、SCN5A、CDH2、FLNC) [<xref ref-type="bibr" rid="hanspub.44050-ref7">7</xref>]。桥粒是心肌和皮肤表皮中丰富的基于钙粘蛋白的特殊细胞–细胞粘附结构。在体外和动物模型中，突变的桥粒引起肌细胞凋亡、纤维化和脂肪生成，从而导致右心室功能受损和致心律失常性增加的机制已得到证实 [<xref ref-type="bibr" rid="hanspub.44050-ref5">5</xref>]。此外，与细胞粘附复合物无关的非桥粒蛋白基因被认为是ARVC/D的常染色体显性遗传形式的原因，例如(1) 心脏ryanodine-2受体基因，负责从肌浆网中释放钙；(2) 转化生长因子-β3基因(TGFβ3)，参与调节细胞外基质的产生和编码染色体蛋白和TMEM43基因的表达 [<xref ref-type="bibr" rid="hanspub.44050-ref8">8</xref>]；(3) 以确定诊断为ARVC/D患者的62个连接分子、5个心脏离子通道、8个结构分子、4个凋亡分子和6个脂肪生成分子的心肌mRNA表达中发现，作为参与细胞内钙处理的分子PLN和p-PLN的表达增加更易诱发室性心律失常 [<xref ref-type="bibr" rid="hanspub.44050-ref9">9</xref>]。这些关于ARVC/D机制的重要新进展有助于解释ARVC/D的弥漫性和渐进性。</p><p>基因检测有助于确定疑似ARVC/D患者的诊断，也有助于确定没有ARVC/D症状但携带该基因缺陷的亲属。另一个优势在于有助于鉴别诊断。基因检测同时具有局限性：(1) 如患者可能有另一种无法识别的遗传缺陷；(2) 与ARVC/D的体征和症状表现最相关的基因是PKP2。然而，这种基因异常可能需要同一基因或另一个桥粒基因的第二次突变才能表现出疾病本身。也就是说，简单的基因鉴定并不能确定它是否是疾病的病因；(3) 无法识别与病理相关的所有基因，以及合并突变的存在，使ARVC/D成为一种遗传上复杂的疾病 [<xref ref-type="bibr" rid="hanspub.44050-ref10">10</xref>]。研究表明通过分析39例ARVC/D患者的蛋白质质谱，得出整合素蛋白β1D蛋白表达减少是室性心动过速(伴有儿茶酚胺易感型)的关键因素 [<xref ref-type="bibr" rid="hanspub.44050-ref11">11</xref>]。梁仕楚等通过生物信息学分析发现IL-6、AIF1、CCL2、CD14、FCER1G、CCR1、PTGS2、FPR1、S100A8、S100A9等10个炎症基因参与ARVC/D病程，主要集中于肿瘤坏死因子信号通路 [<xref ref-type="bibr" rid="hanspub.44050-ref12">12</xref>]。目前通过检测特异基因突变来筛选家族成员的携带者，识别处于临床前阶段患者。所有患有ARVC/D基因异常的个体都应进行定期检查。建议心脏评估从10~12岁开始，因为在此年龄之前疾病表现罕见。检查包括心电图、高分辨率心电图、超声心动图，如有可能，还包括心脏磁共振(cardiac magnetic resonance, CMR)和24小时动态心电图。建议在10~20岁之间每2年重复一次，20岁之后每5年重复一次。在50~60岁之间评估可能会中断，因为该疾病在此年龄组发病罕见 [<xref ref-type="bibr" rid="hanspub.44050-ref10">10</xref>]。</p></sec><sec id="s7"><title>3. 诊断进展</title><p>一般来说，任何有以下表现的年轻或中年患者都应考虑ARVC/D的诊断：(1) 频发心室异位；(2) 室性心动过速伴左束支传导阻滞形态优于或多QRS波形态；(3) SVD。在右侧心前导联出现倒T波的个体在运动过程中发生的心律失常事件中，这一假设得到了印证 [<xref ref-type="bibr" rid="hanspub.44050-ref13">13</xref>]。1994年，制定诊断标准的国际专家组(International Task Force, ITF)提出了ARVC/D的诊断标准，在一种定性评分系统的形式，包括家族、心电图、心律失常、形态功能和疾病特征；2010年，工作组审查了提高诊断敏感性的指南，特别是针对家庭成员的指南(2010 ITF) [<xref ref-type="bibr" rid="hanspub.44050-ref14">14</xref>]，提供右心室异常诊断的定量标准和聚集分子遗传学标准，改善心电图标准 [<xref ref-type="bibr" rid="hanspub.44050-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.44050-ref16">16</xref>]。对五项回顾性研究的系统评价和荟萃分析比较了1994年和2010年标准之间的诊断一致性 [<xref ref-type="bibr" rid="hanspub.44050-ref17">17</xref>]。满足1994年和2010年主要标准的比例分别为8.6%和3.6%，而29.2%和1.9%满足次要标准。与1994年的标准相比，2010年修订的ITF导致满足心血管磁共振标准的患者数量显著减少，诊断为明确ARVC/D的患者数量在统计学上显着增加 [<xref ref-type="bibr" rid="hanspub.44050-ref18">18</xref>]。近年来发现2010ITF诊断由于将分子遗传学发现纳入心电图和影像学而导致过度诊断，以及其他类似ARVC/D表型的疾病的误诊；并且缺乏CMR组织表征结果而导致诊断不足 [<xref ref-type="bibr" rid="hanspub.44050-ref7">7</xref>]。2019ITF提出将CMR作为评估心室室壁运动、收缩功能和心肌组织成分的标准方法，同时增加左室优势型ARVC/D的诊断标准 [<xref ref-type="bibr" rid="hanspub.44050-ref7">7</xref>]。多项调查有助于诊断ARVC/D，初始评估包括非侵入性检查(心电图、高分辨率心电图、超声心动图和/或CMR、24小时动态心电图和基因分析)，而侵入性检查(右心室造影和心内膜活检)仅推荐用于高风险患者 [<xref ref-type="bibr" rid="hanspub.44050-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.44050-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.44050-ref10">10</xref>]。</p><sec id="s7_1"><title>3.1. 心电图</title><p>在心电图中，Epsilon波对ARVC/D具有特异性，尽管它仅在30%的患者中观察到，并且多在右侧心前导联V1-V3中看到 [<xref ref-type="bibr" rid="hanspub.44050-ref18">18</xref>]。特别是，ARVC/D患者aVR导联中的Epsilon波特异性为100% [<xref ref-type="bibr" rid="hanspub.44050-ref19">19</xref>]。在12导联心电图上检测到Epsilon波与持续性VT发生率较高有关，但并不导致SCD发生率增加 [<xref ref-type="bibr" rid="hanspub.44050-ref20">20</xref>]。Epsilon波对心电图的敏感性较低，在25%到38%之间，因此，正常心电图不能排除ARVC/D诊断 [<xref ref-type="bibr" rid="hanspub.44050-ref21">21</xref>]。Fontaine双极心前导联心电图的使用将灵敏度提高到50% [<xref ref-type="bibr" rid="hanspub.44050-ref21">21</xref>]。2018年，Fontaine 提出广义Epsilon波：Presilon波、Topsilon波、Postsilon波；覆盖ARVC/D心室异常除极的全过程，可认为是对Epsilon波定义的补充，能提高ARVC/D诊断敏感性 [<xref ref-type="bibr" rid="hanspub.44050-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.44050-ref23">23</xref>]。此外，ARVC/D心室结构明显异常患者心电图经常表现为：右束支传导阻滞 [<xref ref-type="bibr" rid="hanspub.44050-ref24">24</xref>]。也可以使用更专业的心电图技术，称为信号平均心电图。它旨在通过对心脏产生的多个电信号进行平均来过滤干扰、揭示任何微变化并显示QRS复合波中的晚期电位(如果有)。晚期电位被认为代表电去极化异常，并在2010 ITF中的轻微去极化标准中定义。标准包括：1. 滤波后的QRS持续时间 ≥ 114 ms；2. 终末QRS持续时间 &lt; 40 lV：≥38 ms；3、端子均方根电压40 ms：≤20 lV。需注意的是信号平均心电图并非ARVC/D所特有，因为它也可以在心肌炎和缺血性心脏病中看到 [<xref ref-type="bibr" rid="hanspub.44050-ref18">18</xref>]。</p></sec><sec id="s7_2"><title>3.2. 超声心动图</title><p>有研究表明，ARVC/D早期病理改变有典型区域性，常见于心尖处、右心室前壁漏斗处以及后基底处，随病程进展逐步累及整个右心室，致使患者右心室结构及收缩功能改变，因此对ARVC/D患者心脏结构及功能检查有助于早期诊断及鉴别 [<xref ref-type="bibr" rid="hanspub.44050-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.44050-ref25">25</xref>]。超声心动图可利用3个主要切面：胸骨旁左室长轴切面、心尖四腔心切面以及大动脉短轴切面，动态观察ARVC/D患者心室结构异常，包括整体心室扩张、右心室射血分数降低但左心室正常，或右心室轻度节段性扩张或局部运动减退，有助于疾病早期鉴别 [<xref ref-type="bibr" rid="hanspub.44050-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.44050-ref26">26</xref>]。一起使用超声心动图与心电图诊断ARVC/D，其诊断率均高于单一方法 [<xref ref-type="bibr" rid="hanspub.44050-ref26">26</xref>]。周敏等研究60例ARVC/D患者发现超声心动图斑点跟踪技术更全面客观地反映出心肌运动速度和心肌组织的舒张、收缩能力，计算右心室不同部位在心动周期内的收缩幅度、时相差异，在监测心肌改变中更具敏感性，在ARVC/D患者右心室的功能评价方面具有较好应用前景 [<xref ref-type="bibr" rid="hanspub.44050-ref26">26</xref>]。</p></sec><sec id="s7_3"><title>3.3. CMR</title><p>CMR已成为评估心室容积、收缩功能和区域室壁运动以及表征心肌组织组成的金标准方法 [<xref ref-type="bibr" rid="hanspub.44050-ref7">7</xref>]。由于CMR体素的空间分辨率和可以重建的无限成像平面，CMR提供了右心室的异常和结构变化，最佳评估其扩张/功能障碍、区域壁运动的潜力，在ARVC/D患者早期就可发现心肌壁的运动障碍 [<xref ref-type="bibr" rid="hanspub.44050-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.44050-ref28">28</xref>]。最近的研究证明了结合区域壁运动评估和CMR组织表征在诊断ARVC/D中的实用性：当壁运动改变和对比前/后信号异常时出现最佳准确度(98%)，包括左心室脂肪浸润和晚期钆增强(LGE) [<xref ref-type="bibr" rid="hanspub.44050-ref29">29</xref>]。右心室微动脉瘤和“手风琴信号”的存在，即RVOT或右心室游离三尖瓣下壁的局灶性皱褶，在收缩期更为突出，将ARVC/D的特征异常可视化 [<xref ref-type="bibr" rid="hanspub.44050-ref15">15</xref>]。CMR的不断应用使人们认识到左室的变化比以前认为的更频繁，左室受累主要发生在下壁和基底下外壁，典型表现为脂肪浸润从心外膜向心肌延伸。</p></sec><sec id="s7_4"><title>3.4. 电生理研究</title><p>程序化心室起搏的电生理研究(EFS)在ARVC/D的诊断和治疗评价中应用较少 [<xref ref-type="bibr" rid="hanspub.44050-ref30">30</xref>]。在基线EFS期间，致死性事件有效治疗的发生率在诱导性心律失常患者和非诱导性心律失常患者之间没有显著差异。尽管有这些结果，2010 ITF认为EFS应被考虑用于疑似ARVC/D患者的诊断和评估(IIa类)，也可用于无症状患者的风险分层(IIb类) [<xref ref-type="bibr" rid="hanspub.44050-ref14">14</xref>]。最近的研究使用电解剖电压标测(双极和单极)来评估右心室瘢痕区的存在和范围，这种定位技术在指导活检区域方面被证明是有用的，因为它在识别心肌瘢痕区域方面比CMR更敏感，在鉴别RVOT特发性VT和ARVC/D患者VT方面也更敏感。然而，由于它是一种侵入性、高成本和依赖的操作，此诊断方法应该应用于怀疑指数高和诊断不明确的病例 [<xref ref-type="bibr" rid="hanspub.44050-ref31">31</xref>]。</p></sec><sec id="s7_5"><title>3.5. 心肌组织活检</title><p>2010ITF中使用的组织标准通过心内膜心肌活检获得，侧重于心肌细胞丢失的严重程度和纤维化的量化 [<xref ref-type="bibr" rid="hanspub.44050-ref14">14</xref>]。然而，心内膜心肌活检是侵入性的，由于疾病的异质性和可变分布，其诊断敏感性可能受到限制。尽管右心室游离壁经常受到影响，但由于担心穿孔，通常在隔膜上进行活检，这进一步降低了其敏感性 [<xref ref-type="bibr" rid="hanspub.44050-ref32">32</xref>]。在美国以外，ARVC/D的诊断价值主要在于与其他心肌病、心肌炎和结节病的鉴别诊断。心肌内膜活检仅适用于主要左室受累的先证者和某些散发性ARVC/D，不作为ARVC/D的常规检查 [<xref ref-type="bibr" rid="hanspub.44050-ref33">33</xref>]。右室心内膜电压标测(epicardial voltage mapping, EVM)引导的心内膜心肌活检可提供ARVC/D诊断确认，主要宏观特征显示在心脏移植时外植心脏的短轴截面中，这表明右心室严重扩张，心室壁被脂肪组织广泛取代，有明显的右心室小梁，许多右心室小梁的肌肉组织似乎保留了下来。建议仅用于特殊ARVC/D患者的诊断和准备进行消融治疗的心律失常患者 [<xref ref-type="bibr" rid="hanspub.44050-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.44050-ref33">33</xref>]。</p></sec><sec id="s7_6"><title>3.6. 组织学检测</title><p>ARVC/D患者常见不规则的单核细胞炎症浸润(主要是淋巴细胞浸润)，提示这一过程可能由免疫介导 [<xref ref-type="bibr" rid="hanspub.44050-ref34">34</xref>]。与几种主要表现为心内膜下肌肉受损的心脏病不同，在ARVC/D中，最大的损伤明显表现为右心室游离壁心外膜下区域，此外，在心动周期中经历最大机械应力的右心室游离壁部分受损更严重。一般情况下，右心室心内膜区小梁肌和室间隔(鉴别结节病)是不受累的。当累及左心室时，心外膜下和外侧壁中心肌的退行性变和纤维化更明在组织学方面，该疾病的标志是纤维脂肪置换右心室心肌和室间隔的右心室部分 [<xref ref-type="bibr" rid="hanspub.44050-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.44050-ref34">34</xref>]。</p></sec></sec><sec id="s8"><title>4. 治疗进展</title><p>治疗ARVC/D患者最重要的目标包括：(1) 减少心律失常性SAD或心力衰竭死亡；(2) 预防疾病进展，进而右心室、左心室或双心室功能障碍和心力衰竭；(3) 通过减少/消除心悸、室速复发或从心律转复除颤器(implantable cardioverter defibrillator, ICD)出院来改善症状和生活质量；(4) 限制心力衰竭症状和增加功能容量 [<xref ref-type="bibr" rid="hanspub.44050-ref30">30</xref>]。治疗方法有改善生活方式、药物、导管消融以及ICD。现有证据表明，阴性表型的家庭成员(健康基因携带者或未知基因型)不需要除运动限制外的任何特殊治疗 [<xref ref-type="bibr" rid="hanspub.44050-ref31">31</xref>]。</p><sec id="s8_1"><title>4.1. 药物治疗</title><p>在ARVC/D中，主要目标是避免恶性心律失常和SCD的高危事件，并减缓心力衰竭的进展。ARVC/D患者不应最大限度地锻炼，并警惕任何心悸症状。建议使用抗心律失常药物，如β受体阻滞剂和III类药物 [<xref ref-type="bibr" rid="hanspub.44050-ref35">35</xref>]。胺碘酮单独或联合β-受体阻滞剂(因为它结合了III类抗心律失常和β-肾上腺素能阻断特性的协同效应)是治疗ARVC/D最常用的治疗方案，鉴于长期使用胺碘酮所产生的副作用，索他洛尔是一种很好的治疗选择，特别是在年轻人群中 [<xref ref-type="bibr" rid="hanspub.44050-ref30">30</xref>]。在单药治疗和/或导管消融治疗无效的ARVC/D患者中，加入氟卡尼联合索他洛尔/美托洛尔可能是控制室性心律失常的适当策略 [<xref ref-type="bibr" rid="hanspub.44050-ref36">36</xref>]。患有充血性心力衰竭的个体使用利尿剂和血管紧张素转换酶抑制剂或醛固酮抑制剂进行治疗，并在疾病晚期考虑进行心脏移植。由于存在血栓形成的风险，抗凝剂可用于右心室大、运动缓慢且血流缓慢的ARVC/D患者 [<xref ref-type="bibr" rid="hanspub.44050-ref33">33</xref>]。</p></sec><sec id="s8_2"><title>4.2. ICD应用</title><p>美国心脏病学会、美国心脏协会和欧洲学会和心脏病学会推荐ICD以预防SCD事件 [<xref ref-type="bibr" rid="hanspub.44050-ref33">33</xref>]。国际工作组共识声明提出了ARVC/D植入ICD的风险分层和指征 [<xref ref-type="bibr" rid="hanspub.44050-ref37">37</xref>]。一项研究报告称，植入ICD的ARVC/D患者的年心脏死亡率为0.9% [<xref ref-type="bibr" rid="hanspub.44050-ref38">38</xref>]。一项大型观察性研究表明48%~78%的患者在长期随访中接受了适当的ICD治疗，植入ICD可以提高患者的生存率 [<xref ref-type="bibr" rid="hanspub.44050-ref10">10</xref>]。使用ICD进行早期干预可降低SCD的风险，但ARVC/D是一种进行性疾病，尽管进行了ICD治疗，但仍可进展为难治性/顽固性心律失常或心室颤动 [<xref ref-type="bibr" rid="hanspub.44050-ref8">8</xref>]。</p></sec><sec id="s8_3"><title>4.3. 导管消融术</title><p>使用胺碘酮或ICD治疗后仍无法控制的ARVC/D可行导管消融，针对晚期电位消除的室性心动过速(Ventricular Tachycardia, VT)消融可有效预防伴或不伴右心室结构异常的患者的VT复发 [<xref ref-type="bibr" rid="hanspub.44050-ref10">10</xref>]。三维导航系统的出现使ARVC/D患者的VT消融取得了重大进展。该技术使用彩色组织电压图绘制心内膜和心外膜基质，特别是在与三尖瓣区域和RVOT相邻的区域，根据这一最新经验，ITF建议，心内膜入路不成功，应尝试心外膜入路 [<xref ref-type="bibr" rid="hanspub.44050-ref39">39</xref>]。另一方面，在复发性VT的ARVC/D患者中，心内膜和心外膜联合方法可取得更好的手术成功率和长期无心律失常生存率 [<xref ref-type="bibr" rid="hanspub.44050-ref40">40</xref>]。有研究表明先进行心内膜消融并仅在仍可诱发VT时再逐步进行心外膜消融 [<xref ref-type="bibr" rid="hanspub.44050-ref41">41</xref>]。已发现ARVC/D中导管消融后信号平均心电图的电消退与室性心律失常复发减少 [<xref ref-type="bibr" rid="hanspub.44050-ref42">42</xref>]。</p></sec></sec><sec id="s9"><title>5. 总结</title><p>ARVC/D是一种以右心室心肌纤维脂肪替代为特征的遗传性疾病，可显著增加阵发性室性心律失常和SCD的风险。疑诊的患者要全面地检查评估，结合临床和家族史、心电图和影像学以及基因检测，以明确诊断进一步制定干预策略。目前在治疗方面仅能延缓疾病进展无法治愈，仍面临严峻挑战。需要进一步研究其他治疗方案，如双侧心脏交感神经切断术，采取个性化的患者管理方法，以便在这种高发病率和高死亡率的情况下实施循证医学。</p></sec><sec id="s10"><title>基金项目</title><p>陕西省自然科学基金项目资助(2017SF-125)。</p></sec><sec id="s11"><title>文章引用</title><p>柴俊武,延沁儒,徐静雅,杨承营,曾 迪. 致心律失常性右室心肌病致病基因突变、诊断及治疗研究新进展New Advances in the Research of Pathogenic Gene Mutation, Diagnosis and Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy[J]. 临床医学进展, 2021, 11(07): 3168-3175. https://doi.org/10.12677/ACM.2021.117459</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44050-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Basso, C., Corrado, D., Marcus, F.I. and Nava, A. (2009) Arrhythmogenic Right Ventricular Cardiomyopathy. Lancet, 373, 1289-1300. &lt;br&gt;https://doi.org/10.1016/S0140-6736(09)60256-7</mixed-citation></ref><ref id="hanspub.44050-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Liang, J., Goodsell, K., Grogan, M. and Ackerman, M.J. (2014) LMNA-Mediated _ARVC_ and Charcot-Marie Tooth Type 2B1: A Patient-Discovered Unifying Diagnosis. 35th Annual Heart Rhythm 2014, San Francisco, 4 September 2014, 868-871.</mixed-citation></ref><ref id="hanspub.44050-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., Chen, L., Chen, Z., Chen, X. and Song, J. (2017) Remodelling of Myocardial Intercalated Disc Protein Connexin 43 Causes Increased Susceptibility To malignant Arrhythmias in ARVC/D Patients. Forensic Science International, 275, 14-22. &lt;br&gt;https://doi.org/10.1016/j.forsciint.2017.02.020</mixed-citation></ref><ref id="hanspub.44050-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Saffitz, J.E. (2009) Arrhythmogenic Cardiomyopathy and Abnormalities of Cell-to-Cell Coupling. Heart Rhythm, 6, S62-S65. &lt;br&gt;https://doi.org/10.1016/j.hrthm.2009.03.003</mixed-citation></ref><ref id="hanspub.44050-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Dalal, D., Jain, R., Tandri, H., Dong, J., Eid, S.M., Prakasa, K., et al. (2007) Long-Term Efficacy of Catheter Ablation of Ventricular Tachycardiain Patients with Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. Journal of the American College of Cardiology, 50, 432-440. &lt;br&gt;https://doi.org/10.1016/j.jacc.2007.03.049</mixed-citation></ref><ref id="hanspub.44050-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">房清丽, 李自青, 闫玉清, 高晔, 邢雁霞, 张年萍, 等. 致心律失常性右室心肌病研究进展[J]. 山西大同大学学报: 自然科学版, 2019, 35(5): 44-48.</mixed-citation></ref><ref id="hanspub.44050-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Corrado, D., van Tintelen, P.J., McKenna, W.J., Hauer, R.N.W., Anastastakis, A., Asimaki, A., et al. (2020) Arrhythmogenic Right Ventricular Cardiomyopathy: Evaluation of the Current Diagnostic Criteria and Differential Diagnosis. European Heart Journal, 41, 1414-1429.</mixed-citation></ref><ref id="hanspub.44050-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Romero, J., Mejia-Lopez, E., Manrique, C. and Lucariello, R. (2013) Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC/D): A Systematic Literature Review. Clinical Medicine Insights: Cardiology, 7, 97-114.  
&lt;br&gt;https://doi.org/10.4137%2FCMC.S10940</mixed-citation></ref><ref id="hanspub.44050-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Delmar, M. (2016) ARVC/D and the Dyad: A Long Distance Relationship? Heart Rhythm, 13, 742.  
&lt;br&gt;https://doi.org/10.1016/j.hrthm.2015.11.036</mixed-citation></ref><ref id="hanspub.44050-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Neto, J.E., Tonet, J., Frank, R. and Fontaine, G. (2019) Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D)—What We Have Learned after 40 Years of the Diagnosis of This Clinical Entity. Arquivos Brasileiros de Cardiologia, 112, 91-103. &lt;br&gt;https://doi.org/10.5935/abc.20180266</mixed-citation></ref><ref id="hanspub.44050-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Li, C., Shi, L., Chen, X., Cui, C., Huang, J., et al. (2020) Integrin β1D Deficiency-Mediated RyR2 Dysfunction Contributes to Catecholamine-Sensitive Ventricular Tachycardia in ARVC. Circulation, 141, 1477-1493.  
&lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.119.043504</mixed-citation></ref><ref id="hanspub.44050-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">梁士楚, 王翠, 常龄予, 张士涵, 赵韧, 沈兵. 基于GEO数据库芯片的致心律失常性右室心肌病关键基因筛选与生物信息学分析[J]. 临床心血管病杂志, 2020, 36(6): 516-522.</mixed-citation></ref><ref id="hanspub.44050-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Marcus, F., Edson, S. and Towbin, J.A. (2013) Genetics of Arrhythmogenic Right Ventricular Cardiomyopathy: A Practical Guide for Physicians. Journal of the American College of Cardiology, 61, 1945-1948.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2013.01.073</mixed-citation></ref><ref id="hanspub.44050-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Marcus, F.I., McKenna, W.J., Sherrill, D., Basso, C., Bauce, B., Bluemke, D.A., et al. (2010) Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria. Circulation, 121, 1533-1541. &lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.108.840827</mixed-citation></ref><ref id="hanspub.44050-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Wang, W., James, C.A. and Calkins, H. (2018) Diagnostic and Therapeutic Strategies for Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patient. EP Europace, 21, 9-21.  
&lt;br&gt;https://doi.org/10.1093/europace/euy063</mixed-citation></ref><ref id="hanspub.44050-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Pinamonti, B., Brun, F., Mestroni, L. and Sinagra, G. (2014) Arrhythmogenic Right Ventricular Cardiomyopathy: From Genetics to Diagnostic and Therapeutic Challenges. World Journal of Cardiology, 6, 1234-1244.  
&lt;br&gt;https://doi.org/10.4330/wjc.v6.i12.1234</mixed-citation></ref><ref id="hanspub.44050-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Femia, G., Sy, R.W. and Puranik, R. (2017) Systematic Review: Impact of the New Task Force Criteria in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy. International Journal of Cardiology, 241, 311-317.  
&lt;br&gt;https://doi.org/10.1016/j.ijcard.2017.03.069</mixed-citation></ref><ref id="hanspub.44050-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Li, K.H.C., Bazoukis, G., Liu, T., Li, G., Wu, W.K.K., Wong, S.H., et al. (2018) Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D) in Clinical Practice. Journal of Arrhythmia, 34, 11-22.  
&lt;br&gt;https://doi.org/10.1002/joa3.12021</mixed-citation></ref><ref id="hanspub.44050-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Peters, S. (2015) Prognostic Value of Epsilon Waves in Lead a VR in Arrhythmogenic Cardiomyopathy. International Journal of Cardiology, 191, 77-78. &lt;br&gt;https://doi.org/10.1016/j.ijcard.2015.04.261</mixed-citation></ref><ref id="hanspub.44050-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Protonotarios, A., Anastasakis, A., Tsatsopoulou, A., Antoniades, L., Prappa, E., Syrris, P., et al. (2015) Clinical Significance of Epsilon Waves in Arrhythmogenic Cardiomyopathy. Journal of Cardiovascular Electrophysiology, 26, 1204-1210. &lt;br&gt;https://doi.org/10.1111/jce.12755</mixed-citation></ref><ref id="hanspub.44050-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Yang, B., Chen, H., Ju, W., Chen, K., Zhang, F., et al. (2010) Epsilon Waves Detected by Various Electrocardiographic Recording Methods in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy. Texas Heart Institute Journal, 37, 405-411.</mixed-citation></ref><ref id="hanspub.44050-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">杨丹丹. 广义Epsilon波(178) [J]. 临床心电学杂志, 2019(3): 235.</mixed-citation></ref><ref id="hanspub.44050-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Li, G.L., Saguner, A.M., Akdis, D. and Fontaine, G.H. (2018) Value of a Novel 16-Lead High-Definition ECG Machine to Detect Conduction Abnormalities in Structural Heart Disease. Pacing and Clinical Electrophysiology, 41, 643-655. &lt;br&gt;https://doi.org/10.1111/pace.13338</mixed-citation></ref><ref id="hanspub.44050-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">焦琳, 黄新锐, 吴双, 范倩, 赵芳. 致心律失常型右室心肌病合并左室受累1例报告[J]. 中国循证心血管医学杂志 2020, 12(12): 1530-1531, 1537.</mixed-citation></ref><ref id="hanspub.44050-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">孔令秋, 康彧, 唐红, 付华, 杨庆, 姜建. 超声诊断致心律失常性右心室心肌病的临床价值再评价[J]. 中华超声影像学杂志, 2013, 22(9): 737-740.</mixed-citation></ref><ref id="hanspub.44050-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">周敏, 雍永宏, 姬后亮, 刘剑秋, 高翔, 舒开凤. 超声心动图联合心电图对致心律失常性右室心肌病的诊断价值[J]. 2018, 39(9): 56-59.</mixed-citation></ref><ref id="hanspub.44050-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Haugaa, K.H., Basso, C., Badano, L.P., Bucciarelli-Ducci, C., Cardim, N., Gaemperli, O., Galderisi, M., Habib, G., et al. (2017) Comprehensive Multi-Modality Imaging Approach in Arrhythmogenic Cardiomyopathy—An Expert Consensus Document of the European Association of Cardiovascular Imaging. European Heart Journal-Cardiovascular Imaging, 18, 237-253. &lt;br&gt;https://doi.org/10.1093/ehjci/jew229</mixed-citation></ref><ref id="hanspub.44050-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">沈梦婷, 杨志刚, 叶璐, 刁凯悦, 蒋丽, 张怡. 致心律失常性右室心肌病的磁共振诊断价值及研究进展[J]. 磁共振成像, 2019, 10(6): 469-473.</mixed-citation></ref><ref id="hanspub.44050-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Aquaro, G.D., Barison, A., Todiere, G., Grigoratos, C., Ait Ali, L., Di Bella, G., et al. (2016) Usefulness of Combined Functional Assessment by Cardiac Magnetic Resonance and Tissue Characterization versus Task Force Criteria for Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy. American Journal of Cardiology, 118, 1730-1736.  
&lt;br&gt;https://doi.org/10.1016/j.amjcard.2016.08.056</mixed-citation></ref><ref id="hanspub.44050-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Philips, B. and Cheng, A. (2016) 2015 Update on the Diagnosis and Management of Arrhythmogenic Right Ventricular Cardiomyopathy. Current Opinion in Cardiology, 31, 46-56. &lt;br&gt;https://doi.org/10.1097/HCO.0000000000000240</mixed-citation></ref><ref id="hanspub.44050-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Corrado, D., Link, M.S. and Calkins, H. (2017) Arrhythmogenic Right Ventricular Cardiomyopathy. New England Journal of Medicine, 376, 61-72. &lt;br&gt;https://doi.org/10.1056/NEJMra1509267</mixed-citation></ref><ref id="hanspub.44050-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Corrado, D., Basso, C. and Judge, D.P. (2017) Arrhythmogenic Cardiomyopathy. Circulation Research, 121, 784-802. 
&lt;br&gt;https://doi.org/10.1161/CIRCRESAHA.117.309345</mixed-citation></ref><ref id="hanspub.44050-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">杨丰菁, 刘文玲. 致心律失常性右室心肌病新观点[J]. 实用心电学杂志, 2021, 30(1): 59-63.</mixed-citation></ref><ref id="hanspub.44050-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Asimaki, A., Kleber, A.G. and Saffitz, J.E. (2015) Pathogenesis of Arrhythmogenic Cardiomyopathy. Canadian Journal of Cardiology, 31, 1313-1324. &lt;br&gt;https://doi.org/10.1016/j.cjca.2015.04.012</mixed-citation></ref><ref id="hanspub.44050-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Corrado, D., Wichter, T., Link, M.S., Hauer, R., Marchlinski, F., Anastasakis, A., et al. (2015) Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: An International Task Force Consensus Statement. European Heart Journal, 36, 3227-3237. &lt;br&gt;https://doi.org/10.1093/eurheartj/ehv162</mixed-citation></ref><ref id="hanspub.44050-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Ermakov, S., Gerstenfeld, E.P., Svetlichnaya, Y. and Scheinman, M.M. (2017) Use of Flecainide in Combination Antiarrhythmic Therapy in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy. Heart Rhythm, 14, 564-569.  
&lt;br&gt;https://doi.org/10.1016/j.hrthm.2016.12.010</mixed-citation></ref><ref id="hanspub.44050-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Towbin, J.A., McKenna, W.J., Abrams, D.J., Ackerman, M.J., Calkins, H., Darrieux, F.C.C., et al. (2019) 2019 HRS Expert Consensus Statement on Evaluation, Risk Stratification, and Management of Arrhythmogenic Cardiomyopathy: Executive Summary. Heart Rhythm, 16, e373-e407. &lt;br&gt;https://doi.org/10.1016/j.hrthm.2019.09.019</mixed-citation></ref><ref id="hanspub.44050-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Silvano, M., Corrado, D., Kobe, J., Mönnig, G., Basso, C., Thiene, G., et al. (2013) Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy. Herzschrittmacherther + Elektrophysiol, 24, 202-208.  
&lt;br&gt;https://doi.org/10.1007/s00399-013-0291-5</mixed-citation></ref><ref id="hanspub.44050-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Bai, R., Di Biase, L., Shivkumar, K., Mohanty, P., Tung, R., Santangeli, P., et al. (2011) Ablation of Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Arrhythmia-Free Survival after endo-Epicardial substrate based mapping and ablation. Circulation: Arrhythmia and Electrophysiology, 4, 478-485.  
&lt;br&gt;https://doi.org/10.1161/CIRCEP.111.963066</mixed-citation></ref><ref id="hanspub.44050-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Romero, J., Grushko, M., Briceno, D.F., Natale, A. and Di Biase, L. (2017) Radiofrequency Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). Current Cardiology Reports, 19, Article No. 82.  
&lt;br&gt;https://doi.org/10.1007/s11886-017-0893-3</mixed-citation></ref><ref id="hanspub.44050-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Mussigbrodt, A., Efimova, E., Knopp, H., Bertagnolli, L., Dagres, N., Richter, S., et al. (2017) Epicardial Ablation May Not Be Necessary in All Patients with Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy and Frequent Ventricular Tachycardia. EP Europace, 19, 2047. &lt;br&gt;https://doi.org/10.1093/europace/eux004</mixed-citation></ref><ref id="hanspub.44050-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Liao, Y.C., Chung, F.P., Lin, Y.J., Chang, S.L., Lo, L.W., Hu, Y.F., et al. (2017) The Application of Signal Average ECG in the Prediction of Recurrences after Catheter Ablation of Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. International Journal of Cardiology, 236, 168-173.  
&lt;br&gt;https://doi.org/10.1016/j.ijcard.2017.01.087</mixed-citation></ref></ref-list></back></article>